BME100 f2013:W1200 Group18 L1

BME 100 Fall 2013	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: student Role(s) Name: student Role(s) Name: student Role(s) Name: student Role(s) Name: student Role(s) Name: student Role(s) LAB 1 WRITE-UP Independent and Dependent Variables The independent variable in the experiment is the dosage of the lipopolysaccharide given to the different test groups. This is described as the independent variable because it is different in each group (the variable that is changing). The dependent variable in this experiment is the percentage increase in levels of Inflammotin at each test interval because it changes as the independent variable changes. Experimental Design Groups There are 21 groups ranging from no dose to 9.5 mg. Each group has different intervals of the doseages of the inflammatory inducing drug. The test dosage groups are as follows: 0, .5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5 (all measured in milligrams). Number of subjects per group There are sixteen subjects in each group. Eight of subjects in each group are male and the other eight are female in order to attempt to fully understand how the medication is going to affect both genders. In order to find the lowest affective dosage under 10mg that can be given and still increase the production of inflammotin, a wide range of dosages needed to be administered. According to the groups listed above, each subject would be given the appropriate dosage (depending on their assigned group) of lipopolysaccharide on a daily basis. The subjects will also be given a blood test every three days in order to measure the percentage of change in their Inflammotin levels over a three month period. Once the time period is over, the percentage of change in inflammotin levels will be measured according to the levels at the beginning of the experiment. From there, the lab should be able to effectively decide on how small the dosage can be while still making an impact in inflammotin levels. Subject Selection There will be six female and six male subjects per group and they will be ranging from 65 to 75 years of age. Subjects will be randomly chosen from different back grounds, lifestyles, and races. They will also be tested for pre-existing conditions that could possibly effect the levels of Inflammotin. Sources of Error and Bias (What are some of the potential sources of error or biases that could affect your results and how would you control for them?) One potential source of error are test subjects with pre-existing conditions. Pre-existing conditions can be further complicated when given Lipopolysaccharide and can contribute to changes in Inflammotin levels. Dug allergies can also affect Inflammotin levels. To eliminate these risks, a medical examination testing for pre-existing conditions and drug allergies should be preformed before beginning the drug trial and those that test positive for either should be excluded from the drug trial. Another potential source of error to consider are the different initial levels of Inflammotin in each test subject. Without knowing these values, we can not measure change after the drug has been administered. To solve this, an ELISA test should be preformed on samples of blood from each test subject and initial Inflammotin levels should be recorded. Lastly, Lipopolysaccharide may have limited effects on some patients. By monitoring the test subjects for a period of three months, we will be able to monitor the short and long-term effects on Inflammotin levels.